Menu

Phenotypic CRISPR Screening: Looking Beyond Cell Viability To Study Complex Genetic Interactions

Horizon Discovery invites you to join them for an educational webinar.

Sep 6, 2018
The Scientist Creative Services Team

Phenotypic CRISPR Screening: Looking Beyond Cell Viability To Study Complex Genetic Interactions from thescientistllc on Vimeo.

CRISPR screening, whether using knockout, activation, or inhibition approaches, has become an essential tool for drug discovery. A powerful adaptation of CRISPR screening is created by coupling pooled NGS-linked or arrayed screening strategies with phenotypic measurements. By using an advanced combination of techniques, this screening strategy can be targeted to detect genes that drive complex biological responses via biomarker signal readout or a panel of high content parameters. Scientists at Horizon, the sponsor of this LabTools webinar, have developed both FACS-linked and HCA-based strategies for analysis where cellular pathophysiology is uncoupled from cell health, providing much richer and biologically relevant outcomes. In this webinar, we will discuss data obtained and strategies learned from several successful screens and present ongoing work using increasingly relevant cell models, such as T cells and using single cell RNAseq-based screening approaches.

Topics to be covered:

  • Discussion of the strengths and considerations associated with complex phenotypic screens
  • Examples of successful applications of pooled and arrayed phenotypic screens

Meet the Speakers:

Benedict Cross, PhD
Head of Functional Genomics
Horizon Discovery



Carlos le Sage, PhD
Team Leader
Horizon Discovery



Steffen Lawo, PhD
Team Leader
Horizon Discovery



February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.